Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Demand for Clinical Trials in the Emerging Markets
4.2.2 High R&D Spending of Pharmaceutical Companies
4.2.3 Increasing Number of CROs and Prevalence of Diseases
4.3 Market Restraints
4.3.1 Lack of Adequate Regulatory Framework for Conducting Clinical Trials in some Countries
4.3.2 Stringent Regulations for Patient Enrollment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Service Type
5.2.1 Clinical Trial Site Management
5.2.2 Patient Recruitment Management
5.2.3 Assay Development
5.2.4 Contract Manufacturing
5.2.5 Packaging, Storage and Distribution Services
5.2.6 Commercialization
5.2.7 Other Service Types
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Charles River Laboratories, Inc.
6.1.2 Eurofins Scientific
6.1.3 Laboratory Corporation of America Holdings (Covance Inc.)
6.1.4 PPD Inc.
6.1.5 Alcura Health
6.1.6 Insight Genetics
6.1.7 Parexel International
6.1.8 Icon PLC
6.1.9 IQVIA
6.1.10 WuXi AppTec


7 MARKET OPPORTUNITIES AND FUTURE TRENDS